Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocetinostat and Azacitidine in Relapsed/Refractory Lymphoma
NCT00543582Phase 2Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Oct 2007
- Primary completion
- Mar 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mocetinostat in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by Mirati Therapeutics. Primary endpoint: Overall Response Rate. Started Oct 2007; status: terminated.
02
Drugs
mocetinostat
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00543582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543582.